{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/coronavirus-covid-19/background-information/public-health-response/","result":{"pageContext":{"chapter":{"id":"cd8348b4-2bcc-59c6-9dbf-b420df79dbfd","slug":"public-health-response","fullItemName":"Public Health Response","depth":2,"htmlHeader":"<!-- begin field 3bf8223b-d6b6-4194-a0cc-ab8800f1e2bd --><h2>What has been the public health response?</h2><!-- end field 3bf8223b-d6b6-4194-a0cc-ab8800f1e2bd -->","summary":"","htmlStringContent":"<!-- begin item 0ac4d25a-a680-4195-b6d1-ab8800f1e28a --><!-- begin field b67976c4-f26a-4aa6-9768-ab8800f1e2bd --><ul><li>In China extensive aims at containment of the virus have included lockdown of entire cities, with self-quarantine of suspected infected individuals, restrictions on travel and monitoring large swathes of the population.</li><li>Beyond the confines of China the <a href=\"https://www.who.int/emergencies/diseases/novel-coronavirus-2019\" data-hyperlink-id=\"dc8576df-ffc4-4566-b9b3-ab8800f48099\">World Health Organization</a> (WHO) has coordinated and advised the following measures.<ul><li>Close monitoring for any change in epidemiology.</li><li>Continued intensive source control is needed if there are infections, including isolation of patients and those testing positive for COVID-19, contact tracing and health monitoring, and strict health facility infection prevention and control.</li><li>Intensified active surveillance and reporting for in all countries using the WHO case definition.</li><li>Effective communication strategies to provide people (especially those most at risk) with information for protection, recognition of symptoms, and guidance on when and where to seek treatment.</li><li>Resilience preparation for health systems, anticipating the potential for severe infections.</li><li>Improved serological tests to estimate current and previous infections exposure.</li><li>Research relating to the source of the outbreak to provide evidence necessary for prevention of future viral infections.</li><li>Research into potential treatment and vaccine.</li></ul></li><li>As a result of widespread community transmission, many countries moved to national lockdowns.</li><li>As cases reduced, lockdowns were gradually eased from May in a phased approach in countries including the UK.</li><li>Increases in cases from August, which the UK Government linked to household transmission then led to regional lockdowns throughout the UK.</li><li>On October 23, Wales entered a 17-day national ‘firebreak’ lockdown. On November 5, England entered a second national lockdown, while in Scotland a 5-tier approach of local protection levels started on November 2 to combat a second wave of infections.</li></ul><!-- end field b67976c4-f26a-4aa6-9768-ab8800f1e2bd --><!-- end item 0ac4d25a-a680-4195-b6d1-ab8800f1e28a -->","topic":{"id":"6984fb85-3c40-5450-bda6-7957f9a560d7","topicId":"b76b302e-7ac5-44a1-aad7-ab8700c41ab2","topicName":"Coronavirus - COVID 19","slug":"coronavirus-covid-19","lastRevised":"Last revised in February 2021","chapters":[{"id":"d212a92c-0add-595b-a7d6-5a32867fe5f9","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"1d145562-2683-52db-accf-a80bedd6bb5e","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"c52a3c97-1e7c-58b4-af86-0dd2f0b77865","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"f349cd0f-cb0c-5006-b63f-5a30fdaa06b8","slug":"changes","fullItemName":"Changes"},{"id":"f026a20a-e43c-59e7-883d-f0d7a1dbdd1a","slug":"update","fullItemName":"Update"}]},{"id":"bfc8a3e9-5b8f-5b1f-9059-3f9b1843015d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"1d7208d4-4be1-5109-a3fc-f5fc9070f775","slug":"goals","fullItemName":"Goals"},{"id":"b64f49e4-a62d-56cd-abcb-f82c407e52e7","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"51ea8ac4-fd38-524d-8566-e42974bfa9c4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"216d80a9-a8e3-5739-b592-c2d9ddd176ea","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cde80e77-2bd9-5594-9200-fe3a6fef7fc3","slug":"qipp","fullItemName":"QIPP"},{"id":"a24c3e94-065a-5767-9d41-cb69868045fc","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"18477846-110b-5a6f-844c-2cfa1a84c39f","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a15744df-f80f-5b08-8993-b289c88d56a1","slug":"definition","fullItemName":"Definition"},{"id":"814f7a41-46c7-5e8c-9763-f02d81a30777","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e0a5f4e3-6adc-56a8-a13a-460ca5f3c39a","slug":"complications","fullItemName":"Complications"},{"id":"cd8348b4-2bcc-59c6-9dbf-b420df79dbfd","slug":"public-health-response","fullItemName":"Public Health Response"},{"id":"11cbcb38-8a55-5f6a-8077-321789f26356","slug":"comparison-to-other-infections","fullItemName":"Comparison to Other Infections"},{"id":"448d1049-b54d-50a4-8a5e-aac889069c6f","slug":"disease-progression","fullItemName":"Disease Progression"}]},{"id":"020a4b1b-6b82-532a-8050-185d648bcf7d","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"fc5a288c-4b1e-54d0-8244-d5ca25652c50","slug":"diagnosis","fullItemName":"Diagnosis"}]},{"id":"9ff88f37-df6c-5191-bcfc-dae33da6a3b4","fullItemName":"Management","slug":"management","subChapters":[{"id":"3c0ddcd5-473d-5a66-8ae2-7fa97ad2e887","slug":"suspected-coronavirus-infection","fullItemName":"Scenario: Suspected coronavirus infection"},{"id":"1e4e7529-8d5b-52a4-97cc-a86c6d93dfc8","slug":"immunization","fullItemName":"Scenario: Immunization"},{"id":"e148d0d4-0f10-53c6-94bf-27e92c5eb531","slug":"management-of-other-medical-conditions","fullItemName":"Scenario: Management of other medical conditions"},{"id":"18839f74-7d09-5801-9fc9-1ca496cccf09","slug":"palliative-care","fullItemName":"Scenario: Palliative care"},{"id":"ed0623a0-a868-5776-bbdb-09a5d64bd6d0","slug":"prescribing-issues","fullItemName":"Scenario: Prescribing issues"},{"id":"f6aa749f-0a06-5ca2-b3cd-e01327e4ef76","slug":"managing-long-term-effects","fullItemName":"Scenario: Managing long-term effects"},{"id":"8d7143f7-6842-52e2-8644-5060222c472f","slug":"clinical-resources","fullItemName":"Scenario: Clinical resources"}]},{"id":"ee648ec4-3617-53c8-b0d5-ade1caeb5cfb","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"3ea7d7ae-64e1-581e-856d-9daa5d3570ba","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"d29ccf56-f68d-5ce0-b726-09ba9ed827e7","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"84321e07-ed6b-5815-b7a9-de40ab2acde2","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"cfaeb9ab-79ce-5851-a900-fdd0ab56f8fd","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f73f8f10-2617-514f-b07d-8f52fb8e7f2f","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"586fa044-aa51-5fdc-895a-922bedd17946","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"66b3f0cb-7cb5-5f38-8632-30b8411234e4","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"18477846-110b-5a6f-844c-2cfa1a84c39f","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}